Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant

Cheng, Guang-Shing; Storer, Barry; Chien, Jason W; Jagasia, Madan; Hubbard, Jesse J; Burns, Linda; Ho, Vincent T; Pidala, Joseph; Palmer, Jeanne; Johnston, Laura; Mayer, Sebastian; Crothers, Kristina; Pusic, Iskra; Lee, Stephanie J; Williams, Kirsten M
November 2016
Annals of the American Thoracic Society;Nov2016, Vol. 13 Issue 11, p1932
Academic Journal
journal article
Rationale: The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly characterized. Understanding the trajectory of lung function is necessary for prompt clinical recognition and treatment and also for the rational design of prospective studies.Objectives: To describe the longitudinal trajectory of lung function parameters, including FEV1, in patients with BOS after hematopoietic cell transplant.Methods: Subjects with BOS defined by National Institutes of Health consensus guidelines criteria from a recent multicenter prospective trial of combination treatment with fluticasone, azithromycin and montelukast and a retrospective cohort from Fred Hutchinson Cancer Research Center were included. Longitudinal change in FEV1 for each patient was calculated on the basis of available pulmonary function tests in three periods: pre-BOS, from BOS diagnosis to 6 months, and 6-18 months after diagnosis. The effect of treatment on FEV1 trajectory was analyzed by univariate and multivariate linear regression. The Kaplan-Meier method was used to estimate survival.Measurements and Main Results: The FEV1 percent predicted value at diagnosis was 46% (interquartile range, 35-57%) for trial participants and 53% (interquartile range, 41-64%) for the retrospective cohort. There was a concomitant mild reduction in FVC, as well as a marked reduction in forced expiratory flow, midexpiratory phase, at diagnosis. While there was individual heterogeneity, the overall FEV1 trajectory was characterized by a marked decline within 6 months prior to BOS diagnosis, followed by stability of FEV1 early after diagnosis and a slow rate of decline beyond 6 months. The effect of the trial medications on FEV1 trajectory after BOS diagnosis was a mean rate of change of 0.92% predicted per month (95% confidence interval, -0.53 to 2.37) compared with the retrospective cohort, but this was not statistically significant. Two-year overall survival rates were 76% and 72% for the study participants and the retrospective cohort patients, respectively. Earlier time to diagnosis after hematopoietic cell transplant and severity of FVC at diagnosis were significantly associated with reduced survival.Conclusions: The FEV1 trajectory in patients with BOS after hematopoietic cell transplant in a contemporary era of management follows a predominant pattern of rapid FEV1 decline in the 6 months prior to diagnosis, followed by FEV1 stabilization after diagnosis.


Related Articles

  • Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. Keene, Jason D.; Jacobson, Sean; Kechris, Katerina; Kinney, Gregory L.; Foreman, Marilyn G.; Doerschuk, Claire M.; Make, Barry J.; Curtis, Jeffrey L.; Rennard, Stephen I.; Barr, R. Graham; Bleecker, Eugene R.; Kanner, Richard E.; Kleerup, Eric C.; Hansel, Nadia N.; Woodruff, Prescott G.; Han, MeiLan K.; Paine III, Robert; Martinez, Fernando J.; Bowler, Russell P.; O'Neal, Wanda K. // American Journal of Respiratory & Critical Care Medicine;2/15/2017, Vol. 195 Issue 4, p473 

    Rationale: Chronic obstructive pulmonary disease exacerbations are associated with disease progression, higher healthcare cost, and increased mortality. Published predictors of future exacerbations include previous exacerbation, airflow obstruction, poor overall health, home oxygen...

  • Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Milla, Carlos E.; Ratjen, Felix; Marigowda, Gautham; Fang Liu; Waltz, David; Rosenfeld, Margaret; Liu, Fang; VX13-809-011 Part B Investigator Group * // American Journal of Respiratory & Critical Care Medicine;4/1/2017, Vol. 195 Issue 7, p912 

    Rationale: Combination lumacaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for F508del-CFTR, but it has not been assessed in younger patients.Objectives: In this...

  • Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients. Partanen, A.; Valtola, J.; Ropponen, A.; Kuitunen, H.; Kuittinen, O.; Vasala, K.; Ågren, L.; Penttilä, K.; Keskinen, L.; Pyörälä, M.; Nousiainen, T.; Selander, T.; Mäntymaa, P.; Pelkonen, J.; Varmavuo, V.; Jantunen, E. // Transfusion;Jan2019 Supplement S1, Vol. 59, p325 

    Background: Data are limited on the long-acting granulocyte-colony stimulating factors (G-CSFs) pegfilgrastim (PEG) and lipegfilgrastim (LIPEG) compared with filgrastim (FIL) regarding the mobilization efficiency of CD34+ cells, graft cellular composition, and...

  • A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. Martinez, Fernando J.; Mannino, David; Leidy, Nancy Kline; Malley, Karen G.; Bacci, Elizabeth D.; Barr, R. Graham; Bowler, Russ P.; Han, MeiLan K.; Houfek, Julia F.; Make, Barry; Meldrum, Catherine A.; Rennard, Stephen; Thomashow, Byron; Walsh, John; Yawn, Barbara P.; High-Risk-COPD Screening Study Group * // American Journal of Respiratory & Critical Care Medicine;3/15/2017, Vol. 195 Issue 6, p748 

    Rationale: Chronic obstructive pulmonary disease (COPD) is often unrecognized and untreated.Objectives: To develop a method for identifying undiagnosed COPD requiring treatment with currently available therapies (FEV1 <60% predicted and/or exacerbation...

  • Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. Stanojevic, Sanja; Davis, Stephanie D.; Retsch-Bogart, George; Webster, Hailey; Davis, Miriam; Johnson, Robin C.; Jensen, Renee; Pizarro, Maria Ester; Kane, Mica; Clem, Charles C.; Schornick, Leah; Subbarao, Padmaja; Ratjen, Felix A. // American Journal of Respiratory & Critical Care Medicine;5/1/2017, Vol. 195 Issue 9, p1216 

    Rationale: Implementation of intervention strategies to prevent lung damage in early cystic fibrosis (CF) requires objective outcome measures that capture and track lung disease.Objectives: To define the utility of the Lung Clearance Index (LCI), measured by multiple...

  • Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis. Morgan, Wayne J.; Wagener, Jeffrey S.; Pasta, David J.; Millar, Stefanie J.; VanDevanter, Donald R.; Konstan, Michael W.; Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis // Annals of the American Thoracic Society;Jun2017, Vol. 14 Issue 6, p937 

    Rationale: Children with cystic fibrosis often experience acute declines in lung function. We previously showed that such declines are not always treated with antibiotics, but we did not assess whether treatment improves the likelihood of recovery.Objectives: To...

  • Lung function over the first 3 years of a professional diving career. Skogstad, Marit; Thorsen, Einar; Haldorsen, Tor; Skogstad, M; Thorsen, E; Haldorsen, T // Occupational & Environmental Medicine;Jun2000, Vol. 57 Issue 6, p390 

    Objectives: To characterise diving exposure and pulmonary function in professional divers at the start of their formal education and during the first 3 years of their professional career.Methods: The study included 87 men at the start of their education as professional...

  • Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. GÙell, Maria-Rosa; Cejudo, Pilar; Ortega, Francisco; Puy, M. Carmen; Rodríguez-Trigo, Gema; Pijoan, José Ignacio; Martinez-Indart, Lorea; Gorostiza, Amaia; Bdeir, Khaled; Celli, Bartolome; Galdiz, Juan B.; Güell, Maria-Rosa // American Journal of Respiratory & Critical Care Medicine;3/1/2017, Vol. 195 Issue 5, p622 

    Rationale: In chronic obstructive pulmonary disease (COPD), the benefits of pulmonary rehabilitation (PR) tend to wane over time. Whether maintenance techniques may help sustain the benefits achieved after completion of the initial PR program remains controversial.Objectives:...

  • Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. Bergeron, Anne; Chevret, Sylvie; Granata, Angela; Chevallier, Patrice; Vincent, Laure; Anne Huynh; Tabrizi, Reza; Labussiere-Wallet, Hélène; Bernard, Marc; Chantepie, Sylvain; Bay, Jacques-Olivier; Thiebaut-Bertrand, Anne; Thepot, Sylvain; Contentin, Nathalie; Fornecker, Luc-Matthieu; Maillard, Natacha; Risso, Karine; Berceanu, Ana; Blaise, Didier; Peffault de La Tour, Regis // JAMA: Journal of the American Medical Association;8/8/2017, Vol. 318 Issue 6, p557 

    Importance: Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post-lung transplant bronchiolitis...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics